Charles Schwab Investment Management Inc. Has $60.46 Million Holdings in Balchem Co. (NASDAQ:BCPC)

Charles Schwab Investment Management Inc. grew its stake in shares of Balchem Co. (NASDAQ:BCPC) by 2.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 370,912 shares of the basic materials company’s stock after acquiring an additional 8,942 shares during the period. Charles Schwab Investment Management Inc. owned 1.14% of Balchem worth $60,457,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of BCPC. Atria Investments Inc lifted its position in Balchem by 8.5% during the third quarter. Atria Investments Inc now owns 2,708 shares of the basic materials company’s stock worth $477,000 after acquiring an additional 212 shares during the last quarter. Crossmark Global Holdings Inc. raised its position in shares of Balchem by 20.5% in the third quarter. Crossmark Global Holdings Inc. now owns 3,034 shares of the basic materials company’s stock valued at $534,000 after buying an additional 517 shares in the last quarter. Los Angeles Capital Management LLC raised its position in shares of Balchem by 33.1% in the third quarter. Los Angeles Capital Management LLC now owns 4,588 shares of the basic materials company’s stock valued at $807,000 after buying an additional 1,140 shares in the last quarter. Victory Capital Management Inc. raised its position in shares of Balchem by 129.7% in the third quarter. Victory Capital Management Inc. now owns 98,853 shares of the basic materials company’s stock valued at $17,398,000 after buying an additional 55,822 shares in the last quarter. Finally, Empower Advisory Group LLC raised its position in shares of Balchem by 1.1% in the third quarter. Empower Advisory Group LLC now owns 113,427 shares of the basic materials company’s stock valued at $19,963,000 after buying an additional 1,201 shares in the last quarter. 87.91% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. Sidoti upgraded shares of Balchem to a “hold” rating in a research report on Tuesday, February 25th. StockNews.com downgraded shares of Balchem from a “buy” rating to a “hold” rating in a research report on Tuesday, February 25th. Finally, HC Wainwright reiterated a “buy” rating and issued a $190.00 price target on shares of Balchem in a research report on Monday, February 24th.

Balchem Stock Performance

Shares of NASDAQ:BCPC opened at $167.48 on Thursday. The company’s 50 day simple moving average is $163.42 and its 200 day simple moving average is $169.84. The stock has a market capitalization of $5.45 billion, a price-to-earnings ratio of 42.62, a price-to-earnings-growth ratio of 4.41 and a beta of 0.63. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.99 and a quick ratio of 1.16. Balchem Co. has a 1 year low of $137.69 and a 1 year high of $186.03.

Balchem (NASDAQ:BCPC) last announced its quarterly earnings data on Friday, February 21st. The basic materials company reported $1.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.11 by ($0.08). The firm had revenue of $240.00 million during the quarter, compared to the consensus estimate of $239.96 million. Balchem had a net margin of 13.47% and a return on equity of 11.37%. As a group, research analysts predict that Balchem Co. will post 4.64 EPS for the current fiscal year.

Balchem Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.